Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rivaroxaban.

Puneet Kakar1, Timothy Watson, Gregory Y H Lip

  • 1Haemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, England, UK.

Drugs of Today (Barcelona, Spain : 1998)
|March 24, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evidence guided antiplatelet treatment: time to move from bench to bedside.

Thrombosis research·2009
Same author

Performing repeated noninvasive bedside measures of volume response to intravenous furosemide in acute pulmonary edema: a feasibility assessment.

Cardiovascular therapeutics·2009
Same author

Antiarrhythmic drugs for atrial fibrillation: focus on dronedarone.

Expert review of cardiovascular therapy·2009
Same author

Female gender is a risk factor for stroke and thromboembolism in atrial fibrillation patients.

Thrombosis and haemostasis·2009
Same author

Indications for the use of diagnostic implantable and external ECG loop recorders.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2009
Same author

Ischemic stroke in South Asians: a review of the epidemiology, pathophysiology, and ethnicity-related clinical features.

Stroke·2009
Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023
See all related articles

New oral anticoagulants, like factor Xa inhibitors, offer a safe and effective alternative to warfarin for preventing thrombosis. Rivaroxaban shows promise, potentially reducing the need for routine monitoring in anticoagulant therapy.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Hematology

Background:

  • A need exists for safe, effective oral anticoagulants without routine monitoring.
  • Oral factor Xa inhibitors are a promising class of antithrombotic agents.
  • Warfarin, while effective, requires frequent monitoring.

Purpose of the Study:

  • To evaluate the safety and efficacy of oral factor Xa inhibitors as anticoagulants.
  • To assess the pharmacokinetic and pharmacodynamic profiles of these agents.
  • To explore the potential of rivaroxaban in preventing and treating thromboembolism.

Main Methods:

  • Inhibition of free and clot-bound factor Xa complexes.
  • Dose-dependent prolongation of activated partial thromboplastin time and prothrombin times.

Related Experiment Videos

  • Clinical trials in healthy volunteers and patients for venous and arterial thromboembolism prevention.

    • Main Results:

    • Favorable pharmacokinetic and pharmacodynamic profiles observed in early human studies.
    • Effective inhibition of factor Xa activity with no significant drug accumulation.
    • Rivaroxaban demonstrated a safe and effective profile in venous thromboembolism trials.

    Conclusions:

    • Oral factor Xa inhibitors, such as rivaroxaban, represent a viable alternative to warfarin.
    • These agents offer effective anticoagulation with a favorable safety profile.
    • Further research in phase III trials will clarify their role in arterial thromboembolism prevention.